This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Ray JE, Day RO (1984) J Chromatogr 336:234–238
Friedel HA, Todd PA (1988) Nabumetone: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases, Drugs 35:504–524
Boyle EA, Freeman PC, Mangan FR, Thomson MJ (1982) Nabumetone (BRL 14777, 4-[6-methoxy-2-naphthyl]-bu-tan-2-one): a new anti-inflammatory agent, J Pharm Pharmacol 34:562–569
Mangan FR (1985) A review of the pharmacology of nabumetone, Royal Soc Med Int Congress and Symp Series 69:5–14
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of aspirin-like drugs, Nature (New Biol) 231:232–235
Vane JR (1987) The evolution of non-steroidal anti-inflammatory drags and their mechanism of action, Drugs 33(Suppl 1): 18–27
Mangan FR, Flack JD, Jackson D (1987) Preclinical overview of nabumetone pharmacology, bioavailability, metabolism and toxicology, Am J Med 86(Suppl 4B):6–10
DeardenJC, Nicholson RM (1984) Correlation between gastric irritancy and anti-inflammatory activity of non-steroidal anti-inflammatory drugs, J Pharm Pharmacol 36:713–715
Huston GJ (1985) Local buccal mucosal effects of aspirin, naproxen, and nabumetone, Royal Soc Med Int Congress Symp Series 69:43–46
Lussier A, LeBel E (1987) Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin and nabumetone, Am J Med 83(Suppl 4B): 15–18
Garner A (1977) Mechanisms of action of aspirin on the gastric mucosa of the guinea pig, Acta Physiol Scand:101-110
Jackson RE, Mitchell FN, Brindley DA (1987) Safety evaluation of nabumetone in United States clinical trials, Am J Med 83(Suppl 4B):115–120
Jenner PN, Johnson ES (1987) Review of the experience with nabumetone in clinical trials outside the United States, Am J Med 83(Suppl 4B): 110–114
Dandona P, Jeremy J Y (1990) Nonsteroidal anti-inflammatory drag therapy and gastric side effects: does nabumetone provide a solution? Drags 40(Suppl 5): 16–24
Freeman AM, Undre NA, Thawley AR, Golding DN (1985) Plasma and synovial fluid concentrations of nabu-metone and BRL 10720 in patients given nabumetone, Royal Soc Med Int Congress Symp Series 69:37–42
Brobyn RD (1987) Nabumetone in the treatment of active adult rheumatoid arthritis. Am J Med 83(Suppl 4B):50–54
Appelrouth DJ, Bairn S, Chang RW, Cohen MH, Englund DW, Germain BF, Hartmann SS, Jaffer A, Mullen BJ, Smith FE (1987) Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults, Am J Med 83(Suppl 4B):78–81
Pisko EJ, Bockow BI, Box P, Brodsky AL, Burch FX, Collins RL, Fleischmann RM, Keller MI, Lipani JA, Poiley JE (1987) Six-month multicenter study comparing nabumetone and naproxen in the treatment of osteoarthritis, Am J Med 83(Suppl 4B):86–91
Carle WK, Rotman H (1985) General practice study of nabumetone and indomethacin in patients with osteoarthritis, Royal Soc Med Int Congress Symp Series 69:139–148
Wade AG, Fletcher DM (1985) Comparison of nabumetone and indomethacin in the treatment of patients in general practice with osteoarthritis, Royal Soc Med Int Congress Symp Series 69:149–160
Von Schrader HW, Buscher G, Dierdorf D, Mugge H, Wolf D (1983) Nabumetone — a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses, Int J Clin Pharmacol Ther Tox 21:311–321
Nandi KL, Corless D, Undre NA, Thawley AR (1985) A study of the pharmacokinetics, effectiveness, and tolerance of nabumetone, a novel anti-inflammatory drug, in elderly patients, Royal Soc Med Int Congress Symp Series 69:163–172
McMahon FG, Vargas R, Ryan JR, Fitts DA (1987) Nabumetone kinetics in young and elderly patients, Am J Med 83(Suppl 4B):92–95
Bourke B, Undre NA, Thawley AR (1985) An investigation into the penetration of nabumetone and its metabolites into synovial fluid in patients with rheumatoid arthritis, Royal Soc Med Int Congress Symp Series 69:31–35
Jackson D, Hardy TL, Langley PF, von Schrader HW (1985) Pharmacokinetic, toxicological, and metabolic studies with nabumetone, Royal Soc Med Int Congress Symp Series 69:15–27
Boelaert JR, Jonnaert HA, Daneels RF, Schurgers ML, Thawley AR, Undre NA, Cooper DL (1987) Nabumetone pharmacokinetics in patients with varying degrees of renal impairment, Am J Med 83(Suppl 4B): 107–109
Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR (1984) Metabolism of nabumetone (BRL 14777) by various species including man, Xenobiotica 14:327–337
Rainsford KD (1984) Side effects of anti-inflammatory/ analgesic drugs. Epidemiology and gastro-intestinal tract, Trends Pharmacol Sci 5:156–159
O’Brien WM, Bagby GF (1985) Rare adverse reactions to nonsteroidal anti-inflammatory drugs, J Rheumatol 12:13–20, 347-353, 562-567, 785-790
Rainsford KD, Velo GP (Hrsg.) (1984) Side effects of anti-inflammatory/analgesic drugs, Raven Press, New York
Rainsford KD, Velo GP (Hrsg.) (1987) Side effects of anti-inflammatory drugs, Bd. I und II, MTP Press, Lancaster
Rainsford KD (1987) Toxicity of currently used anti-inflammatory and anti-rheumatic drugs. In: Lewis AJ, Furst DE (Hrsg.) Newer anti-inflammatory drugs, Dekker, New York, S.215–244
Rainsford KD (1988) Current concepts of the mechanisms of side effects of nonsteroidal anti-inflammatory drugs as a basis for establishing research priorities. An experimentalist’s view, J Rheumatol 15(Suppl. 17):63–70
Ishikawa H, Tabusa F, Miyamoto H, Kano M, UedaH, Tamaoka H, Kazuyuki N (1989) Chem Pharm Bull 37:2103–2108
Akamatsu H, Sasaki H, Kurokawa I, Nishijima S, Asada Y und Niwa Y (1995) Effect of Nadifloxacin on Neutrophil Functions J of Int Med Res 23/1:19–26
Vogt K, Hahn H, Hermann J, Haustein UF, Blume U, Gollnick H und Orfanos CE (1995) Antimicrobial Evaluation of Nadifloxacin (OPC-7251), a New Topical Quinolone, in Acne Vulgaris Drugs 49(Suppl 2):266–268
Nishijima S, Namura S, Akamatsu H, Kawai S, Asada Y, Kawabata S und Fujita M (1995) In vitro activity of Nadifloxacin against both Methicillin-Susceptible and-Rcsistant Clinical Isolates of Staphylococcus aureus from Patients with Skin Infections Drugs 49(Suppl 2):230–232
Daten der Firma Galderma (s. Fachinformation zu Nadifloxacin)
Bojar RA, Hittel N, Cunliffe WJ, Holland KT (1995) Direct Analysis of Resistance in the Curaneous Microflora during Treatment of Acne Vulgaris with Topical 1 % Nadifloxacin and 2 % Erythromycin Drugs 49(Suppl 2): 164–167
Takahashi N, Shibahara T, Shiragiku T, Kanbe T, Kanbe K, Sugawara M, Yamashita S (1995) Reduction of in vitroClastogenicity induced by the mixture of optical isomers of nadifloxacin during storage. Arzneimittelforschung 45/2, 195–197
Björk I, Lindahl V (1982) Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 48:161–182
Oosta GM, Gardner WT, Beeler DL, Rosenberg RD (1981) Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA 78:829–833
Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G (1983) Structure-activity relationship in heparin: a synthetic pentasaccaride with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Bio-phys Res Commun 116:492–499
Cerskus AL, Birchall KJ, Ofosu FA, Hirsh J, Blajchman MA (1984) Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III. Canad J Biochem Cell Biol 62:975–983
Abildgaard U (1993) Heparin/Low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 23(suppl 1):103–106
Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh NA, Gaffney PJ (1983) Heparin and a low weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 30:219–224
Fareed J, Walenga JM, Williamson K, Martine-Emanuele R, Kumar A, Hoppensteadt DA (1985) Studies on the anti-thrombotic effects and pharmacokinetics of heparin fractions and fragments. Semin Thromb Hemost 11:56–74
Doutremepuich C, Gestreau JL, Maury MO, Quilichini R, Boisseau MR, Toulemonde F, Vairel E (1983) Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction. Haemostasis 13:109–112
Fareed J, Kumar A, Walenga JM, Emanuele RM, Williamson K, Hoppensteadt D (1984) Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv Rev Fr Hémat 26:267–275
Weichen W, Breddin HK (1988) Effect of low-molecular weight heparins on laser-induced thrombus formation in rat mesenteric vessels. Haemostasis 18(suppl 3):55–63
Brace L, Fareed J (1985) An objective assessment of the interaction of heparin and its fractions with human platelets. Semin Thromb Hemost 11:190–198
Heinrich D, Görg T, Schulz M (1988) Effects of unfrac-tionated and fractionated heparin on platelet function. Haemostasis 18, suppl. 3:48–54
Harenberg J, Würzner B, Zimmermann R, Schettler G (1986) Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res 44:549–554
(1995) Fraxiparine®. Nadroparin Calcium PH. Eur. Technical Brochure. Sanofi Pharma
Kakkar VV, Murray WJG (1985) Efficacy and safety of low-molecular weight heparin (CY 216) in preventing postoperative venous thrombo-embolism: a cooperative study. Brit J Surg 72:786–791
The European Fraxiparin Study Group (EFS). Publishing Commitee: Encke A, Breddin HK, Koppenhagen K, Klempa I et al. (1988) Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein, thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Br J Surg 75:1058–1063
Aoyama T, Okutome T, Nakayama T, Yaegashi T, Matsui R, Nunomura S, Kurumi M, Sakurai Y, Fujii S (1985) Chem Pharm Bull 33:1458–1471
Arakawa K, Kurotori M, Sugiyama S, Kurumi M, Aoyama T (1985) Yakugaku Zasshi 105:512–516
Aoyama T, Sasaki H, Shibuya M, Suzuki Y (1985) Chem Pharm Bull 33:2142–2144
Fuji S, Hitomi Y (1981) Biochim Biophys Acta 661:342–345
Kurotori M, Arakawa K, Sugiyama S, Kurumi M, Aoyama T (1985) Yakugaku Zasshi 105:470–474
Ono H, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Sakai Y, Kiriyama S, Sobajima H (1990) Dig Dis Sci 35:787–792
Mar 31, S 1730
Drugs Fut (1985) 10(7):565-569
Nestor JJ Jr (1984) Development of agonistic LHRH and its analogs, Lancester, MTP Press 3–10
Henzel MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J (1988) Administration of nasal nafarelin as compared with oral danazol for endometrio-sis, New England J of Medicine 318(8):485–489
Hoffman PG, Henzel MR, Chaplin MD, Nerenberg CA (1987) Clinical development of Nafarelin acetate phase I and phase II studies; J Androl 8:17–22
Drugs Fut (1976) 1(7):339-353
Moody DE, Reddy JK (1978) The hepatic effects of hypo-lipidemic drugs (clofibrate, nafenopin, fibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-as-sociated enzymes. Am J Pathol 90:435–450
Levine WG, Braunstein HR, Meijer DK (1975) Effect of nafenopin (SU-13,437) on liver function: mechanism of choleretic effect. Naunyn Schmiedebergs Arch Pharmacol 290:221–234
Meijer DK, Bognacki J, Levine WG (1975) Effect of nafenopin (SU-13,437) on liver function: influence on the hepatic transport of organic anions. Naunyn Schmiedebergs Arch Pharmacol 290:235–250
Reddy JK, Rao MS (1977) Malignant tumors in rats fed nafenopin, a hepatic peroxisome proliferator. J Natl Cancer Inst 59:1645–1550
Izquierdo A, Bosch E, Rodrigo V (1982) Talanta 29:1125–1129
Clarke EGC (1975) Isolation and Identification of Drugs, Vol. 2, 1. Aufl., The Pharmaceutical Press, London, S.1066
Kracmar J, Kracmarova J (1979) Pharmazie 34:27–32
Bosch E, Cassasas E, Izquierdo A, Roses M (1984) Anal Chem 56:1422–1428
Klein-Soyer C, Bloy C, Archiproff G, Beretz A, Cazenave JP (1995) Naftazone accelerates human saphenous vein endothelial cell proliferation in vitro. Nouv Rev Fr Hemat-ol 37:187–192
Berson I (1977) Etude clinique d’un nouveau veinotrope: le mediaven (naftazone). Schweiz Rundsch Med Prax 66:180–181
Meszaros T (1977) Plethysomographische Untersuchung von Beinbeschwerden unter Einnahme von Ovulations-hemmern und ihre Behandlung mit Mediaven (DCI Naftazone). Schweiz Rundsch Med Prax 66:209–213
Drug Fut (1987) 12:31-33
Kutscher B, Engel J, Fleischhauer I, Niebch G (1993) Arch Pharm 326:803–806
Sponer G, Borbe HO, Muller-Beckmann B, Freud P, Jakob B (1992) Naftopidil, a new adrenoceptor blocking agent with Ca2+-antagonistic properties: interaction with adreno-
Alarayyed NA, Cooper MB, Prichard BN, Betteridge DJ, Smith CC (1997) In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine. Br J Clin Pharmacol 43:415–420
Pescalli N, Sala V, Spooner G, Ceserani R (1996) Effects of naftopidil on some urodynamic parameters and arterial blood pressure in comparison with prazosin in conscious rats. Pharmacol Research 34:121–124
Grundke M, Himmel HM, Wettwer E, Borbe HO, Ravens U (1991) Characterization of Ca2+ antagonistic effects of three metabolites of the new antihypertensive agent naftopidil. J Cardiovasc Pharmacol 18:918–925
Takeda T, Kouno M, Iimimur O, Yoshinaga K, Kuramoto K (1992) The study of clinical effect and optimal dose of naftopidil (KT-611) in essential hypertension. Rinsho Iya-ku 8(Suppl 3):65–88
Takeda T, Kouno M, Iimimira O, Yoshinaga K, Kuramoto K (1992) The clinical effect of naftopidil (KT-611) in the long-term treatment of essential hypertension. Rinsho Iya-ku 8(Suppl 3): 123–145
Yasuda K, Amanishi T, Toho M, Nagashim K, Akimoto S, Shimazaki J (1994) Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. Prostate 25:46–52
Peter G, Niebch G, Locher M, Borbe HO (1991) Pharma-cokinetic fate of the novel antihypertensive drug naftopidil. Arzneimittel-Forschung 41:924–931
Farthing MJG, Alstead EM, Abrams SML, Haug G, Johnston A (1994) Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. Postgraduate Med J 70:363–366
Drugs Fut (1984) 9(7):518-519
Hermann EC, Lee KT, Myers MJ (duPont de Nemours, E.I. and Co.) Eur Pat Appl 39,066; Jpn K 81,167,678; US K4,322,426; zit. aus Lit.1
Gal TJ, DiFazio CA (1986) Prolonged antagonism of opi-oid action with intravenous nalmefene in man. Anesthe-siology 64:175–180
Konieczko KM, Jones JG, Barrowcliffe MP, Jordan C, Altman DG (1988) Antagonism of morphine-induced respiratory depression with nalmefene. Br J Anaesth 61:318–323
Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D, Weidler D (1987) Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 27:233–239
Michel ME, Bolger G, Weissman BA (1985) Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 7:175–177
Feldman M, Moore L, Walsh JH (1985) Effect of oral nalmefene, an opiate-receptor antagonist, on meal-stimulated gastric acid secretion and serum gastrin concentration in man. Regul Pept 11:245–250
Graham SH, Shimizu H, Newman A, Weinstein P, Faden AI (1993) Opioid receptor antagonist nalmefene stereo-specifically inhibits glutamate release during global cerebral ischemia. Brain Res 632:346–350
Gal TJ, DiFazio CA, Dixon R (1986) Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther 40:537–542
Dixon R, Howes J, Gentile J, Hsu HB, Hsiao J, Garg D, Weidler D, Meyer M, Tuttle R (1986) Nalmefene: intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther 39:49–53
Glass PS, Jhaveri RM, Smith LR (1994) Comparison of potency and duration of action of nalmefene and nal-oxone. Anesth Analg 78:536–541
Kaplan JL, Marx JA (1993) Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study. Ann Emerg Med 22:187–190
Stone NN (1994) Nalmefene in the treatment of interstitial cystitis. Urol. Clin North Am 21:101–106
(1995) Product Information Revex®, Nalmefene Ohmeda Pharmaceutical Products, Liberty Corner NJ
Monroe EW (1989) Efficacy and safety of nalmefene in patients with severe pruritis caused by chronic urticaria and atopic dermatitis [see comments]. J Am Acad Dermat-ol 21:135–136
Fudala PJ, Heishman SJ, Henningfield JE, Johnson RE (1991) Human pharmacology and abuse potential of nalmefene. Clin Pharmacol Ther 49:300–306
Portoghese PS, Sultana M, Nagase H, Takemori AE (1988) J Med Chem 31:281–282
Calcagnetti DJ, Holtzman SG (1991) Delta opioid antagonist, naltrindole, selectively blocks analgesia induced by DPDPE but not DAGO or morphine. Pharmacol Biochem Behav 38:185–190
Portoghese PS, Nagase H, MaloneyHuss KE, Lin CE, Takemori AE (1991) Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole. J Med Chem 34:1715–1720
Shah S, Davis T, Yoburn BC (1994) The effect of naltrindole on spinal and supraspinal delta opioid receptors and analgesia. Life Sci 55:1451–1458
Stapelfeld A, Hammond DL, Rafferty MF (1992) Antino-ciception after intracerebroventricular administration of naltrindole in the mouse. Eur J Pharmacol 214:273–276
Suzuki T, Tsuji M, Mori T, Misawa M, Nagase H (1995) Effect of naltrindole on the development of physical dependence on morphine in mice: a behavioral and biochemical study. Life Sci 57:PL247–252
Kitchen I, Pinker SR (1990) Antagonism of swim-stress-induced antinociception by the delta-opioid receptor antagonist naltrindole in adult and young rats. Br J Pharmacol 100:685–688
Krishnan Sarin S, Jing SL, Kurtz DL, Zweifel M, Portoghese PS, Li TK, Froehlich IC (1995) The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology Berl. 120:177–185
Leventhal L, Kirkham TC, Cole JL, Bodnar RJ (1995) Selective actions of central mu and kappa opioid antagonists upon sucrose intake in sham-fed rats. Brain Res 685:205–210
Kelley AE, Bless EP, Swanson CJ (1996) Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats. J Pharmacol Exp Ther 278:1499–1507
Piepponen TP, Ahtee L (1995) Effects of selective opioid receptor antagonists on morphine-induced changes in striatal and limbic dopamine metabolism. Pharmacol To-xicol 77:204–208
Ossipov MH, Kovelowski CJ, Vanderah T, Porreca F (1994) Naltrindole, an opioid delta antagonist, blocks the enhancement of morphine-antinociception induced by a CCKB antagonist in the rat. Neurosci Lett 181:9–12
Funada M, Schutz CG, Shippenberg TS (1996) Role of delta-opioid receptors in mediating the aversive stimulus effects of morphine withdrawal in the rat. Eur J Pharmacol 300:17–24
Heidbreder C, Shoaib M, Shippenberg TS (1996) Differential role of delta-opioid receptors in the development and expression of behavioral sensitization to cocaine. Eur J Pharmacol 298:207–216
Menkens K, Bilsky EJ, Wild KD, Portoghese PS, Reid LD, Porreca F (1992) Cocaine place preference is blocked by the delta-opioid receptor antagonist, naltrindole. Eur J Pharmacol 219:345–346
Mousseron M (1959) US Pat 2882201, zit. nach CA (1959) 53:170841
MI 12
Wenner W (1950) J Org Chem 15:548
Southwick PL, Pursglove WA, Pursglove BM, Walsh WL (1954) J Am Chem Soc 76:754
Ogata Y, Ishiguro J (1950) J Am Chem Soc 72:4302
Gore RC, Hannah RW, Pattacini SC, Porro TJ (1971) Journal of the AOAC 54:1040–1082
Archer TE, Stokes JD (1983) J Agric Food Chem 31:268–288
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London
Karlsson MO, Dahlstrom B, Neil A (1988) Characterization of high-affinity binding sites for the antitussive [3H]noscapine in guinea pig brain tissue. Eur J Pharmacol 145:195–203
Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2
Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2
DHU, Karlsruhe (1994) S. 214-215
Voisin H (1969) Materia medic ades hom. Praktikers, Haug Verlag Heidelberg: S. 872
Keller K, Greiner S, Stockebrand P (1990) Hom. AM, Govi-Verlag: Bd. 2
Keller K, Greiner S, Stockebrand P (1990) Hom. AM, Govi-Verlag: Bd. 2
DHU, Karlsruhe (1994) S. 216-217
Voisin H (1969) Materia medica des hom. Praktikers; Haug-Verlag Heidelberg: S. 879–884
Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2
Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2
Boericke W (1994) Horn. Mittel und ihre Wirkungen, Wis-senschaftl. Autorenverlag Leer/Ostfriesland: S. 357-358
Voisin H (1969) Materia medica des hom. Praktikers, Haug-Verlag, Heidelberg: S. 884
Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2
Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 2
Boericke W (1994) Horn. Mittel und ihre Wirkungen, Wis-senschaftl. Autorenverlag Leer/Ostfriesland: S. 358-359
DHU, Karlsruhe (1994) S. 218-219
Voisin H, Materia medica des hom. Praktikers, Haug Verlag: S. 885-887
Keller K, Greiner S, Stockebrand P (1990) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2
Keller K, Greiner S, Stockebrand P (1990) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2
Voisin H (1969) Materia medica des hom. Praktikters Haug-Verlag, Heidelberg: S. 888–892
Boericke W (1994) Hom. Mittel und ihre Wirkungen, Wis-senschaftl. Autorenverlag Leer/Ostfriesland: S. 360-361
Keller K, Greiner S, Stockebrand P (1990) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2
Keller K, Greiner S, Stockebrand P (1990) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2
Voisin H (1969) Materia medica des hom. Praktikers, Haug-Verlag Heidelbergr S. 245–250
Boericke W (1994) Horn. Mittel und ihre Wirkungen; Wissenschaftl. Autorenverlag Leer/Ostfriesland: S. 99
Keller K, Greiner S, Stockebrand P (1995) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2
Keller K, Greiner S, Stockebrand P (1995) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2
Brockhaus R, Essigsäure. In: Ull Bd. 11, S.68
Mar 29, S. 1025
Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf
Banie S (1981) Cancer Lett 11:239
Fukushima S, Imaida K, Sakata T, Okamura T, Shibata M-A, Ito N (1983) Cancer Res 43:4454
Fukushima S, Shibata M, Shiran T, Tamano S, Ito N (1986) Cancer Res 46:1623
Cohen SM, Ellwein LB, Okamura T, Masui T, Johansson SL, Smith RA, Wehner JM, Khachab M, Chappel CI, Shoenig GP (1991) Cancer Res 51:1766
Buettner GR (1993) Arch Biochem Biophys 300:535
Filehne W (1901) Cloetta’s Lehrbuch der Arzneimittellehre und Arzneiverordnungslehre, Verlag von JCB Morh, Tübingen Leipzig, S. 128
Eichholtz F (1942) Lehrbuch der Pharmakologie, Springer-Verlag, Berlin, S. 379
Naeije N, Bracamonte M, Michael O (1983) Crossdesensi-tisation between aspirin and benzoate in asthma, Lancet ii: 1035–1036
Mar 29, S. 1618
Braune G, Schneider H Natriumcarbonat und Natriumhy-drogencarbonat. In: Ull Bd. 17, S. 159 ff
Mar 29, S. 1614
Gmelin’s Handbuch der Anorganischen Chemie (1964) Natrium, System-Nr.: 21, Erg. Bd. 1, 8. Aufl., Verlag Chemie, Weinheim, S. 309
Braune G, Schneider H Natriumcarbonat und Natriumhy-drogencarbonat. In: Ull Bd. 17, S. 159 ff
Hollemann AF, Wiberg E, Lehrbuch der anorganischen Chemie, Walter de Gruyter Verlag, Berlin, S.427ff
Remy H; Lehrbuch der anorganischen Chemie, 9. Aufl., Bd. 1, Akademische Verlagsgesellschaft, Leipzig, S.232
Scanion EF, Milland FP, Hellman L (1990) J Surg Oncol 44(1):47–51
Widmer LK, Hurlimann F, Duchosal F (1967) Anfiologica 4(3-4):193–202
Mar 31, S. 1467
Danon D, Marikovsky Y, Gasko O (1966) 51-Chromium uptake as a function of red cell age. J Lab Clin Med 67:70–77
Langard S, Norseth T. In: L. Friberg, G.R Nordberg, V.B. Vouk (editors) Handbook on the toxicology of metals. El-sevier Amsterdam. 383
Roche M, Perez-Gimenez E, Layrisse M, Diprisco E (1957) Study of urinary and fecal excretion of radioactive Cr-51 in man. J Clin Invest 36:1181–1192
Heimpel H, Keiderling W, Schoeppe W, Reichhold H, Hoffmann G (1961) Untersuchungen zur Bestimmung der Erythrozytenüberlebenszeit und des Abbauortes der Erythrozyten bei Gesunden mit Hilfe der Cr-51-Markierung in vitro und in vivo. Nucl med 2:217–233
Adam W (1981) Die Bestimmung der Erythrozytenle-benszeit und des Erythrozytenabbauortes. Der Nuklearmediziner 42:161–168
Najean Y (1981) Die Bestimmung des Blutvolumens und ihre praktische Bedeutung in der klinischen Hämatologie. Der Nuklearmediziner 42:115–122
Pachter KGR, Matlok F, Gremiich HU (1988) Merck FT-IR-Atlas, VCH Verlagsgesellschaft, Weinheim, S. 884
Datenblatt zu IR 3.295/83, E. Merck, Darmstadt/ Schu-chardt&Co
Ganguly SC: J Indian Chem Soc 15 (1938) 611; Chem Zbl 1939 I, 4.816
Sträub FB (1935) 42 Hoppe-Seyler’s Z physiol Chem 236
Arbeitsanleitung zum UV-Test L-Äpfelsäure, Test-Combination Nr. 139068 Boehringer Mannheim (1989)
Schweckendiek W (1984) Die Psoriasis vulgaris, eine stoffwechselbedingte Hautkrankheit, Erfahrungsheilkunde 33, 850–858
Mrowietz U, Christophers E, Altmeyer P (1998) Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study, Brit J Dermatol 138, 456–460
Niboer C, De Hoop D, Langendijk PNJ, Van Loenen AC, Gubbels J (1990) Fumaric acid therapy in psoriasis: a double blind comparison between fumaric acid compound therapy and monotherapy with dimethyl-fumaric acid ester, Dermatologica 81, 33–37
Bayard W, Hunziker T, Krebs A, Speiser P, Joshi R (1987) Perorale Langzeitbehandlung der Psoriasis mit Fumarsäu-rederivaten, Hautarzt 38, 279–285
Raab W (1984) Psoriasis-Behandlung mit Fumarsäure und Fumarsäureestern, Z Hautkr 59, 671–679
Rudenko MI, Andriushkin VN, Artemov VG (1994) The use of mafusol in acute blood loss, Voen Med Zh 33-34
Lure GO, Osipov VP, Charnaia MA (1990) The use of new soviet crystalloid mafusol as a hemodiluent in surgery using artificial circulation, Anesteziol Reanimatol 20-22
Selivanov EA, Khanevich MD, Starokon PM, Slepneva LV, Zybina NN (1992) Activation of the processes of the lipid peroxidation in the small intestinal mucosa and liver in peritonitis and possible ways of their correction by a complex infusion-detoxification therapy, Gematol Transfuziol 37, 13–16
Walker CB, Niebloom TA, Socransky SS (1979) Agar medium for use in succeptibility testing of bacteria from human periodontal pockets, Antimicrob Agents Chemother 16, 452–457
Bernhard T, Gottschalk G (1978) Cell yields of Escheri-chia coli during anaerobic growth on fumarate and molecular hydrogen, Arch Microbiol 116, 235–238
Lauter WM, Brucar MO; USP 2,543,976; zit. nach CA 489 le
Scott KN (1972) J Am Chem Soc 94:8564–8568
Ebel S (1977) Handbuch der Arzneimittelanalytik, Verlag Chemie, Weinheim, New York, S. 111
Elks J, Ganellin CR (Hrsg.) (1990) Dictionary of Drugs, 1. Aufl., Chapman and Hall, London New York Tokyo Melbourne Madras, S. 413
Mar 31, S. 1753
Sewester CS, Olin BR, Hebel SK, Connell SI, Dombek CE, Kastrup EK (1990) Drug facts and comparisons, Lip-pincott Company, St. Louis, Missouri:S. 133–136
Kurz H (1986) Elektrolyte und Infusionslösungen, In: Ammon HPT (Hrsg.) Arzneimittelneben-und Wechselwirkungen, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, S. 547–556
Ruoff HJ (1986) Antazida, In: Ammon HPT (Hrsg.) Arz-neimittel-Neben-und Wechselwirkungen, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart: S594–599
Methoden der enzymatischen Lebensmittelanalytik (1975/19) Lebensmittelanalytik, Boehringer, Mannheim
Sporns P (1982) J Assoc Off Anal Chem 65(3):567–571, zit. nach CA (1982) 97:4757c
Rhys Williams AT, Winfield SA (1982) Analyst (London) 107(1978):1092–1094, zit. nach CA (1982) 97:214366a
Gal S, Schilling P (1972) Z Lebensm Unters Forsch 148(1):18–22, zit. nach CA 76:98061n
Nakanishi H (1983) J Assoc Off Anal Chem 66(6):1528–1531, zit. nach CA (1984) 100:21629k
Curry KK, Evans JW, Schwab G (1983) HRC CC J, High Resolut Chromatogr Commun 6(9):510–511; zit. nach CA 99:224450d
Merck (1992/1993) Katalog Reagenzien, Diagnostica, Chemikalien
Hochgeschwender K, Zimgiebl E, Natriumhydroxid. In: Ull Bd. 17, S. 210 ff
Mar 29, S. 1617
Schreiner S (1982) Schwefel-Sauerstoff-Säuren, Kap. 5. 1-Hydroxyalkansulfite. In: Ullmanns Encyklopädie der technischen Chemie, Verlag Chemie, Weinheim, 4. Aufl., Bd. 21, S. 112; s. auch Süss HU (1985) Bleaching. In: llmann’s Encyclopedia of industrial chemistry, 5. Aufl., Vol. A4, S. 196
Beilstein 1, a) 577, b) I 302, c) II 642, d) III 2583, e) IV 3052
Gmelins Handbuch der Anorganischen Chemie (1964) Verlag Chemie Weinheim, 8. Aufl., Na, 21, a) Erg. Bd. 1, S. 256-257
Gmelins Handbuch der Anorganischen Chemie (1966) Verlag Chemie Weinheim, 8. Aufl., Na, 21, b) Erg. Bd. 3, S. 1071-1073
Sachs AP (1938) US Pat 2,135,474
Van Nerom CG, Bormans GM, De Roo MJ, Verbruggen AM (1993) First experience in healthy volunteers with techneticum-99m-L,L-ethylendicysteine, a new renal imaging agent, Eur J Nucl Med 20:738–746
Maini CL, Antonacci P, Sargiotto A, Castellano G, Podio V (1989) Dynamic renal scanning using 99mTc-MAG-3 in man, Eur J Nucl Med 15:635–640
Blaufox MD (1972) Evaluation of renal function and disease with radionuclides In: Potchen ED, McCready VR (Eds.). Progress in Nuclear Medicine. Basel
Dumont M, Marchand L, Laroche B, Robert G, Thabet M (1990) Scintigraphic evaluation of renal function after extracorporeal shock-wave lithotripsy. Can Assoc Radiol J 41:138–140
Sfakianakis GN, Bourgoignie JJ, Jaffe D, Kyriakides G, Perez-Stable E, Duncan RC (1987) Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension. J Nucl Med 28:1383–1392
Grant ME, Herron KG, MacDougall ML, Preston DF, Moore WV, Wiegmann TB (1991) Single-dose subcutaneous iodine-131-iodohippurate for determination of renal plasma flow. J Nucl Med 32:1452–1454
Russell CD, Dubovsky EV, Scott JW (1989) Estimation of ERPF in adults from plasma clearance of 131 I-hippuran using a single injection and one or two blood samples. Int J Rad Appl Instrum B 16:381–383
Lear JL, Feyerabend A, Gregory C (1989) Two-compartment, two-sample technique for accurate estimation of effective renal plasma flow: theoretical development and comparison with other methods. Radiology 172:431–436
Le Cloirec J, Devillers A, Rivallan J (1994) Les explorations isotopiques dans la surveillance du transplant renal. J Radiol 75:15–17
ICRP (1987) Annals of the ICRP. Band 18; ICRP Publ. Nr. 53
Bhargava KK, Acharya SA (1989) Labeling of monoclonal antibodies with radionuclides. Semin Nucl Med 19:187–201
B Anz (1990) 143:3951
Husakova M, Laznicek M, Kvetina J (1989) Cesk Farm 38(1):26–28
Kulkarni PV, Corbett JR (1990) Semin Nucl Med 20(2):119–129
Poser D (1977) Jahresbericht des Vereins für Kernverfahrenstechnik und Analytik, Dresden, S. 71-72
Buttermann G (1987) Ergebnisse der Radioiodtherapie benigner Schilddrüsenerkrankungen. In: Radioiodtherapie bei Schilddrüsenerkrankungen. G. Buttermann (Hrsg:). pmi-Verlag Frankfurt:55–73
Börner W, Eichner R, Reiners C, Ruppert G, Schaffhauser R, Seybold K (1978) Zur Diagnostik und Therapie des Schilddrüsenmalignoms. Therapiewoche 28:9272
Schlegel G, Wendt T (1981) Differenzierte Therapie des Schilddrüsenkarzinoms. Diagnostische Aspekte in der Nachsorge. Tumor Diagnostik 3:122
Moser E, Fritsch S, Kreisig T (1987) Diagnostik, Therapie und Nachsorge des Schilddrüsenkarzinoms: Nuklearmedizinische Aspekte. In: Radioiodtherapie bei Schilddrüsenerkrankungen. G. Buttermann (Hrsg.) pmi-Verlag Frankfurt:79–94
Bell E (1979) Therapie der Hyperthyreose mit I 131 bei diffuser Struma. Der Nuklearmediziner 4:214
Buttermann G (1987) Heutiger Stellenwert der Radiotherapie in der Behandlung der thyreoidalen Autonomie — Indikationen, Alternativen, Ergebnisse. In: Radiotherapie bei Schilddrüsenerkrankungen. G. Buttermann (Hrsg.). pmi-Verlag Frankfurt:37–54
Dobyns MB et al. (1974) Malignant and benign neoplasms of the thyroid in PTS treated for hyperthyroidism: A report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol 38:976
Edmonds CJ, Smith T (1986) The long-term hazards of the treatment of thyroid cancer with radioiodine. Brit J Radiol 59:45
Van Nostrand D, Neutze J, Atkins F (1986) Side effects of rational dose iodine 131-therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 27:10
Shaw SM (1985) Drugs and diseases that may alter the biodistribution or pharmacokinetics of radiopharmaceuticals. Pharmacy International, December 1985:293
Brin (1953) Biochem Prepar 3:61
Richterich R, Colombo JP (1978) Klinische Chemie, 4. Aufl., S. Karger, München
Boehringer Test-Kombination L-Milchsäure (L-Lactat) Nr. 139084
Cassanas G, Morssli M, Fabregue E, Bardet L (1991) J Raman Spectroscopy 22:409–413
Heinerth E, Silicate. In: Ull Bd. 21, S. 412 ff
Hag Bd. II, S. 1034
Gmelin’s Handbuch der Anorganischen Chemie (1935) Molybdän, System-Nr. 53, 8. Aufl., Verlag Chemie, Weinheim, S. 214 ff
Sebenik RF, Dorfler RR, Laferty JM (1990) Molybdenum and Molybdenum Compounds. In: Elvers B, Hawkins S; Schulz G (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A16, VCH Verlagsgesellschaft, Weinheim, S. 663
Mitchell PCH (1990) ibd., S. 675
Gmelin’s Handbuch der Anorganischen Chemie (1935) Molybdän, System-Nr. 53, 8. Aufl., Verlag Chemie, Weinheim, S.214 ff
Mitchell PCH (1990) Molybdenum and Molybdenum Compounds. In: Elvers B, Hawkins S; Schulz G (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A16, VCH Verlagsgesellschaft, Weinheim, S. 675
Karklins P, Pelcmane I, Ramina L (1984) Latv PSR Zinat Akad Vestis 10:108–112, zit. nach CA 102(5):4434w
Baniel AM, Eyal AM (1991) Eur Pat Appl EP 432.610, EP 90-123.108, zit. nach CA 115(15): 157,166z
Laue W, Thiemann M, Scheibler E, Wiegand KW (1991) Nitrates and Nitrites. In: Elvers B, Hawkins S, Schulz G (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A17, VCH Verlagsgesellschaft, Weinheim, S. 266 ff
Korn Bd. 1, S. 105
Mar 29, S. 1617
Brandt W, Catholy G, Buennig R, Wittstock D (1986) Ger. (East) DD 237, 310; zit. nach CA (1987) 107:6774e
Brandt W, Bruennig R, Catholy G, Wittstock D (1986) Ger. (East) DD 237,308; zit. nach CA (1987) 107:39210w
Nelson, Cretcher (1930) Am Soc 52:3703
FIDES Laboratorio M, Cuatrecases (1965) Span 302,338 zit. nach CA (1966) 65:15169e
Arendaruk AP, Serebryakov LA, Skoldinov AP (1963) Med Prom SSSR 17(6):6–8; zit. nach CA (1963) 33:11234d
Morssli M, Cassanas G, Bardet L, Pauvert B, Terol A (1991) Spectrochim Acta, Part A 47A(5):529–541; zit. nach CA (1991) 115:81100a
Simkovic I, Alfoldi J, Matulova M (1986) Carbohydr Res 152:137–141
Migonney V, Lacroix MD, Ratner BD, Jozefowicz M (1995) J Biomater Sci Polym Ed 7(3):265–275; zit. nach CA 123:40894j
Kimura Y, Yamane H, Komatsuzaki S (1994) Jpn Kokai Tokkyo Kohe JP 06,336,523; zit. nach CA (1995) 122:274142u
Hansson A (1961) Acta Chem Scand 15:934
Bertsch-Frank B (1991) Peroxo Compounds, Inorganic. In: Elvers B, Hawkins S; Schulz G (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A19, VCH Verlagsgesellschaft, Weinheim, S. 182 ff
Mar 29, S. 1618
Gallone P (1986) Chlorine Oxides and Chlorine Oxygen Acids. In: Gerhartz W (Hrsg.) Ullmanns’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A6, VCH Verlagsgesellschaft, Weinheim, S.515 f
Gemlin’s Handbuch der Anorganischen Chemie (1970) Natrium, System-Nr.: 21, Erg. Bd. 5, 8. Aufl., Verlag Chemie, Weinheim, S. 1781
Aanderud S, Sundsfjord J, Aarbakke J (1984) Amiodaron inhibits conversions of T4 to T3 in isolated rat hepatocytes. Endocrinol 115:1605–1608
Anbar M, Guttmann S, Lewitus Z (1959) The mode of action of perchlorate ions on the iodine uptake of the thyroid gland. Int J Appl Radiat 7:87–89
Bartalena L, Brogioni S, Grasso L, et al. (1996) Treatment of amiodarone-induced thyreotoxicosis, a difficult challenge: Results of a prospective study. J Clin Endocrinol Metab 81:2930–2933
Broekhuysen J, Laruel R (1969) Research on the benzofuran series XXXVIII: Comparative study of transit and metabolism of amiodarone in different species of animals and humans. Arch Int Pharmacodyn 177:340–359
Eichler O, Hackenthal E (1962) Über Ausscheidung und Stoffwechsel von Perchlorate gemessen mit 36 C104. Naunyn-Schm Arch Exp Pathol Pharmakol 243:554–565
Goldman SJ, Stanbury JB (1973) The metabolism of perchlorate in the rat. Endocrinol 92:1536–1538
Martino E, Aghini-Lombardi F, Mariotti S, et al. (1986) Treatment of amiodarone-induced thyreotoxicosis by simultaneous administration of potassium perchlorate and methimazole J Endocrinol Invest 9:201–207
Martino E, Aghini-Lombardi F, Mariotti S, et al. (1987) Amiodarone: a common source of iodine-induced thyreotoxicosis. Horm Res 26:158–171
Mazonson PD, Williams ML, Cantley MK, et al. (1984) Myxedema coma during long-term amiodarone therapy. Am JMed 77:751–754
Postel S (1957) Placental transfer of perchlorate and triiodo-thyronine in the guinea pig. Endocrinol 60:53–66
Smyrk TC, Goellner JR, Brennan MD, et al. (1987) Pathology of the thyroid in amiodarone-associated thyreotoxicosis. Am J Surg Path 11:197–204
Trotter WR (1962) The relative toxicity of antithyroid drugs. J New Drugs 2:333–343
Wolff J (1998) Perchlorate and the thyroid gland. Pharmacol Rev 50:89–105
Wolff J, Maury JR (1963) Thyroidal iodide transport: The role of ion size. Biochim Biophys Acta 69:58–67
Wyngaarden JB, Wright BM, Ways P (1952) The effect of certain anions upon the accumulation and retention of iodide by the thyroid gland. Endocrinol 50:537–549
Reich E, Bogl KW (1989) Nuklearmedizin 28(5):201–207
Mar 31, S. 1467
Intenzo CM, Park CH, Cohen SN (1990) Clin Nucl Med 15(5)313–314
Beierwaltes WH (1990) J Nucl Med 31(4):400–402
Berke RA, Johnson RM, Henegar GC (1967) Am J Roentgenol Radium Ther Nucl Med 100(4):844–846
Atkins HL, Thomas SR, Buddemeyer U, Chervu LR (1990) J Nucl Med 31(3):378–380
Mar 31, S. 1467
Glaubitt D (1979) 32P-Behandlung der Polycythaemia rubra vera. Der Nuklearmediziner 4, 2:255–267
Pfannenstiel H (1979) Endolymphatische Behandlung mit P-32-I-131. Der Nuklearmediziner 4, 2:300–313
Sikov MR et al. (1958) Anomalous Development Induced in the Emryonic Rat by the Maternal Administration of Radiophosphorus. Am J Anat. 103:137–162
Keeling DH, Sampson CB (1984) Adverse Reactions to Radiopharmaceuticals. United Kingdom 1977–1983. Br J Radiol. 57:1091–1096
Rhodes BA et al. (1980) Adverse Reactions Radiopharmaceuticals. J Nucl Med 21, 11:1107
Montz R (1978) Therapie mit 32Phosphor. In: L. Diethelm, F. Heuck, O. Olsson, F. Strnad, H. Vieten, A. Zuppinger (Hrsg) Nuklearmedizin, Teil 2. Diagnostik, Therapie, Klinische Forschung. Springer, Berlin, Heidelberg, New York (Handbuch der medizinischen Radiologie)
Lawrence JH (1940) Nuclear Physics and Therapy: Preliminary Report on a New Method for the Treatment of Leukemia and Polycythemia. Radiology 35:51–60
Haas H, Phosphoroxide, Phosphorsäuren und Phosphate. In: Ull Bd. 18, S. 320 ff
Komm DAB 7-DDR (1964) Akademie-Verlag, Berlin
Pouchert CJ (1985) The Aldrich Library of FT-IR-Spectra, 1.Aufl.
Kommentar Europäisches Arzneibuch, 7. Aufl., Bd. III, Govi-Verlag 1982, S. 613-616
Hansen PE, Thiessen H, Brodersen R (1979) Acta Chem Scand B 33:281–293
Pachaly P (1983) Dünnschichtchromatographie in der Apotheke, Wissenschaftliche Verlagsgesellschaft mbH, 2. Aufl., Stuttgart, S. 160
Eppert G, Liebscher G, Ihrke M, Arendt G (1985) J Chromatogr 350:471–476
Schleuder M, Beyrich T (1974) Pharmazie 29:448–452
Eger K, Aengstenheyster G, Gegenbach R (1978) Dtsch Apoth Ztg 118:1047–1048
Kim M, Stewart, JT (1990) J Liquid Chromatogr 13:213–237; zit. nach CA 113:29381n
Carlson M, Thompson RD (1987) J Liquid Chromatogr 10:997–1009; zit. nach CA 107:84008x
Europäisches Arzneibuch, 2. Ausgabe
Registry of Toxic Effects of Chemical Substances (RTECS): V05075000
Pharmeuropa (1996) 8(1):79-81
McGreevy PB, Marsden PD (1986) Protozoan infections of man, american trypanosomiasis and leishmaniasis. In: Chemotherapy of parasitic diseases, edited by Campbell WC and Rew RS. Plenum Press: New York and London 1986:115–127
WHO (1982) Report of the informal meeting of the chemotherapy of visceral leishmaniasis, WHO Offset Publ. TDR/Chemleish/VL 82.3:19 pp
Chulay JD, Bhatt SM, Muigai R, Ho M, Gachihi G, Were JBO, Chunge C, Bryceson ADM (1983) A comparison of three dosage regimens of sodium stibigluconate in the treatment of visceral leishmaniasis in Kenya. J Infect Dis 148:148–155
Rees PH, Keating MI, Kager PA, Hochmeyer WT (1980) Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 2:226–229
WHO (1983) Report on the workshop on chemotherapy of old world cutaneous leishmaniasis, WHO Offset Publ. TDR/Leish/CL-JER/ 83.3:19 pp
Thakur CP (1984) Epidemiological, clinical and therapeutic feature of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 78:391–398
Bryceson ADM (1970) Diffuse cutaneous leishmaniasis in Ethiopia: II. Treatment Trans R Soc Trop Med Hyg 64:369–379
Chulay JD, Oster CN, McGreevy PB, Kreutzer RD, Hendricks LD (1988) American cutaneous leishmaniasis: Clinical presentation and problems of patient managment. Rev Soc Bras Med Trop 21:165–172
Oster CN, Chulay JD, Hendricks LD, Pamplin CL, Ballou WR, Berman JD, Takafuji ET, Tramont EC, Canfield CJ (1985) American cutaneous leishmaniasis: A comparison of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg 34:856–860
Rocha RAA, Sampaio RN, Guerra M, Magalhaes A, Cuba CC, Barreto AC, Marsden PD (1980) Apparent glucantime failure in five patients with mucocutaneous leishmaniasis. J Trop Med Hyg 83:131–139
Sampaio RNR (1984) Tratamento hospitalar de leishmaniose cutaneo-mucosa. Masters thesis, Universidade Federal de Belo Horizonte.
Marsden PD, Sampaio RNR, Carvalho EM, Veiga JPT, Costa JLM Llanos-Cuentas EA (1985) High continuous antimony therapy in two patients with unresponsive mucosal leishmaniasis. Am J Trop Med Hyg 34:710–713
Gagliardi ART, Veiga JPR, Rosa TT, Marsden PD (1985) Pentavalent antimony inhibiton of water transport by the toad bladder. Bras J Med e Biol Res
Sampaio RNR, Rocha RAA, Marsden PD, Cuba CC, Barreto AC (1980) Leishmaniose tegumentar americana: Casuistica do Hospital escola da UnB Ann Brasil Dermatol 55:69–76
Teworte W, Natriumsulfat und Natriumhydrogensulfat. In: Ull, Bd. 17, S.211 ff
Gmelin’s Handbuch der Anorganischen Chemie (1928) Natrium, System-Nr. 21, 8. Aufl., Verlag Chemie Weinheim, Belin, S. 560
Hag. Bd. Vla, S.140f
Merck-Katalog Reagenzien, Diagnostica, Chemikalien 1992/93
Gmelin’s Handbuch der Anorganischen Chemie (1928) Natrium, System-Nr. 21, 8. Aufl., Verlag Chemie, Weinheim, S. 520
Pistor H, Knippschild G, Meffert A, Rasch J, Bor-Verbi düngen, anorganische. In: Ull Bd. 8, S. 663 ff
Smith RA (1985) Boric Oxides, Boric Acid and Borati In: Gerhartz W (Hrsg.) Ullmann’s Encyclopedia of Indu rial Chemistry, 5. Aufl., Bd. A4, VCH Verlagsgesellscha Weinheim, S. 273
Mar 29, S. 1548
Smith RA (1985) Boric Oxides, Boric Acid and Borates. In: Gerhartz W (Hrsg.) Ullmann’s Encyclopedia of Industrial Chemistry, 5. Aufl., Bd. A4, VCH Verlagsgesellschaft, Weinheim, S. 270 ff
Pistor H, Knippschild G, Meffert A, Rasch J, Bor-Verbindungen, anorganische. In: Ull Bd. 8, S. 663 ff
Theis G, Thiocyansäure und anorganische Thiocyanate. In: Ull Bd. 23, S. 163 ff
Hag Bd. II. S. 966, Bd. VIa, S. 133
U.S. pat. 2,895,988 (1959, Sterling Drug) CA 54:1.445
McChesney EW, Banks WF Jr (1974) Urinary excretion of Three Oral Cholecystographic Agents in Man, Proc Soc Exp Biol Med 119:1027–1030
Berk RN, Loeb PM, Cobo Frenkel A, Barnhart JL (1977) The biliary and urinary excretion of sodium tyropanoate and sodium ipodate in dogs: pharmacokinetics, influence of bile salts and choleretic effects with comparison to iopanoic acid. Invest Radiol 12:85–95
Cooke WJ, Cooke LM (1983) Biliary and urinary excretion of tyropanoic acid and its metabolites in the dog. Invest Radiol 18:285–292
McChesney EW, Banks WF Jr (1974) Urinary excretion of Three Oral Cholecystographic Agents in Man. Proc Soc Exp Biol Med 119:1027–1030
Fischer HW, Burgener FA (1974) Fractionated dose administration schedule for cholecystography. Invest Radiol 9:24–31
Fon GT Hunter TB, Berk RN, Capp MP (1980) The effect of diet and fasting on gallbladder opacification during oral cholecystography in dogs as measured by computed tomography. Radiology 136:585–592
Berk RN, Loeb PM (1976) Pharmacology and physiology of the biliary radiographic contrast materials. Semin Roentgenol 11:147–156
Oliphant M, Whalen JP, Evans JA (1974) Time of optimal gall-bladder opacification with bilopaque (tyropanoate sodium). Radiology 112:531–532
Muhlethaler CA, Gerlock AJ Jr., Amberg JR, Avant GR (1982) Radiographic appearance of the nonabsorbed (unconjugated) and conjugated sodium tyropanoate (Bilopaque) in the bowel. Invest Radiol 17:506–509
Muhlethaler CA, Gerlock AJ Jr., Avant GR (1981) Conjugated sodium tyropanoate (Bilopaque) in the bowel: significance of its presence or absence after first dose oral cholecystography. Radiology 141:311–316
Thoeni RF, Moss AA (1982) A clinical trial of oral cholecystography using combinations of contrast agents and two consecutive doses. Radiology 144:271–275
Felicetta JV, Green WL, Nelp WB (1980) Inhibition of hepatic binding of thyroxine by cholecystographic agents. J Clin Invest 65:1032–1040
Felicetta JV, Czanko R, Huber-Smith MJ, McCann DS (1986) Cholecystographic agents and sulfobromophthalein inhibit the binding of L-thyroxine to plasma membranes of rat hepatocytes. Endocrinology 118:2500–2504
Felicetta JV, Green WL, Huber-Smith MJ (1983) Effects of cholecystographic agents and sulfobromophthalein on binding of thyroid hormones to serum proteins. J Clin Endocrinol Metab 57:207–212
Noguchi K, Suzuki H, Nakahata M, Kurosawa S, Nakagawa S (1986) Prolonged treatment of hyperthyroidism with sodium tyropanoate, an oral cholecystographic agent: a re-evaluation of its clinical utility. Clin Endocrinol (Oxf) 25:293–301
Hoppe JO, Ackerman JH, Larsen AA, Moss J (1970) Sodium tyropanoate. A new oral cholecystographic agent. J Med Chem 13:997–999
Van Lommen GRE, De Bruyn MFL, Schroven MFJ (Jansen Pharm.N.V.) AU 8436326, EP 145067, JP 85132977, US 4654362, zit. nach (1989) Drug Fut 14:957-959
Van Lommen GRE, De Bruyn MFL, Schroven MFJ (1990) J Pharm Belg 45:355–360
Janssens WJ (1992) Pharmacology of nebivolol. J Pharm Belg 47:323–327
Stoleru L, Wijns W, van Eyll C, Bouvy T, Van Nueten L, Pouleur H (1993) Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with D-L-nebivolol and atenolol. J Cardiovasc Pharmacol 22:183–190
Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM (1995) Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/No-dependent mechnism. J Pharmacol Exp Ther 274:1067–1071
Pauwels PJ, Van Gompel P, Leysen JE (1991) Human beta 1-and beta 2-adrenergic receptor binding and mediated accumulation of cAMP in transfected Chinese hamster ovary cells. Profile of nebivolol and known beta-adrenergic blockers. Biochem Pharmacol 42:1683–1689
Chan TY, Woo KS, Nicholls MG (1992) The application of nebivolol in essential hypertension: a double-blind randomized, placebo-controlled study. Int J Cardiol 35:387–395
Laeourciere Y, Poirier L, Lefebvre J, Provencher P, Arnott W (1992) Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 32:660–666
Lacourciere Y, Arnott W (1994) Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens 8:283–288
Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P (1993) Long-term (3-month) effects of a new beta-blokker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 21:1094–1100
De Cree J, Van Nueten L, Geukens H, Verhaegen H (1992) Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers. Int J Clin Pharmacol Res 12:159–163
Van Bortel LM, Breed JG, Joosten J, Kragten JA, Lustermans FA, Mooij JM (1993) Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmaco 21:856–862
Drugs Fut (1987) 12(8):758-759
Davis R, Whittington R, Bryson HM (1997) Drugs 53:608–636
Ellingrod VL, Perry PJ (1995) Am J Health-Syst Pharm 52:2799–2812
Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Frank DY (1995) J Clin Psychiatry 56(Suppl 6):3–11
Greene DS, Barbhaiya RH (1997) Drug Disposition 33:260–275
Malik K (1996) J Psychopharmacol 10(Suppl 1):1–4
Eison AS, Eison MS, Torrente JR (1990) Psychopharmacol Bull 26:311–315
Rickeis K, Robinson DS, Schweizer E, Marcus RN, Roberts DL (1995) J Clin Psychiatry 56(Suppl 6):43–46
Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminara JA, Marcus RN (1996) J Clin Psychiatry 57(Suppl 2):31–38
Mendels J, Reimherr F, Marcus RN, Roberts DL, Francis RJ, Anton SF (1995) J Clin Psychiatry 56(Suppl 6):30–36
Preskorn SH (1995) J Clin Psychiatry 56(Suppl 6): 12–21
Fawcett J, Marcus RN, Anton SF, O’Brien K, Schwiderski U (1995) J Clin Psychiatry 56(Suppl 6):37–42
Olausson P, Ericson M, Petersson A, Kosowski A, Soderpalm B, Engel JA (1998) Alcohol 15:77–86
Armitage R, Yonkers K, Cole D, Rush AJ (1997) J Clin Psychopharmacol 17:161–168
Sharpley AL, Williamson DJ, Attenburrow MEJ, Pearson G, Sargent P, Cowen PJ (1996) Psychopharmacology (Berl) 126:50–54
Montgomery SA (1996) J Psychopharmacol 10(Suppl 1):5–10
Dockens RC, Greene DS, Barbhaiya RH (1996) J Clin Pharmacol 36:160–167
Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH (1995) J Clin Psychopharmacol 15:399–408
Barbhaiya RH, Shukla UA, Natarajan CS, Behr DA, Greene DS, Sainati SM (1995) Clin Pharmacol Ther 58:390–398
Ferry N, Bernard N, Cuisinaud G, Rougier P, Trepo C, Sassard J (1994) Fundam Clin Pharmacol 8:463–473
Drugs Fut (1987) 12(8):758-759
Kamihara S, Kaneuchi T, Uchiyama K, Terada T, EP 574952, zit. nach CA (1994) 120:298463
Betzing H, Biedermann J, Materne C, Neuser V, DE 2924011, zit. nach CA (1981) 94:156740
Fujimaki Y, Sudo K, Hakusui H (1992) J Chromatogr 575(2):261–268
Fujimaki Y, Sudo K, Tachizawa H (1988) J Chromatogr 433:235–242
Drugs Fut (1989) 14(1):17-18
Fujimaki Y, Hasimoto K, Sudo K (1990) Biotransformation of a new pyrrolidinone cognition-enhancing agent: isolation and identification of metabolites in human urine. Xenobiot 20:1081–1094
Fujimaki Y, Sudo K, Hakusui H et al. (1992) Single-and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers. J Pharm Pharmacol 44:750–754
Fujimaki Y, Sudo K, Hakusui H (1995) In vitro metabolism of nefiracetam by liver microsomes from rats, dogs and monkeys. Arzneim Forsch 45:748–752
Fujimaki Y, Sudo K, Hakusui H (1993) Pharmacokinetics of nefiracetam and three metabolites in humans and stereoselective hydroxylation of its pyrrolidine ring. Xenobiot 23:61–70
Harada S, Sakaguchi Y, Shimada M et al. (1995) Male reproductive toxicity study of nefiracetam in rats. J Toxicol Sci 20:309–317
Huang CS, Ma JY, Marszalec W et al. (1996) Effects of the nootropic drug nefiracetam on the GABA A receptorchannel complex in dorsal root ganglion neurons. Neuropharmacol 35:1251–1261
Joshii M, Watabe S, Sakurai T et al. (1997) Cellular mechanisms underlaying cognition-enhancing actions of nefiracetam (DM-9384). Behav Brain Res 83:185–188
Joshii M, Watabe S (1994) Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells. Brain Res 642:123–131
Nabeshima T, Tohyama K, Kameyama T (1990) Effects of DM-9384, a pyrrolidone derivative, on alcohol-and chlordiazepoxide-induced amnesia in mice. Pharmacol Biochem Behav 36:233–236
Nabeshima T, Tohyama K, Murase K et al. (1991) Effects of DM-9384, a cyclic derivative of GABA, on amnesia and decreases in GABA A and muscarinic receptors induced by cycloheximide. J Pharmacol Exp Ther 257:271–275
Nishizahki T, Matsuoka T, Nomura T et al. (1998) Nefiracetam modultes acetylcholine receptor currents via two different signal transduction pathways. Mol Pharmacol 53:1–5
Odumeru O, Murphy KJ, O’Connell AW et al. (1997) Influence of nefiracetam on NGF-induced neuritogenesis and neural cell adhesion molecule polysialic acid expression: in vivo and in vitro comparisons. Behav Brain Res 83:173–178
Sakurai T, Kato T, Mori K et al. (1998) Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: an in vivo microdialysis study. Neurosci Lett 246:69–72
Shimada H, Hattori C, Tanaka N et al. (1994) Mutagenicity study of the new cognition-enhancing agent nefiracetam. Arzneim Forsch 44:251–253
Watabe S, Yamaguchi H, Ashida S (1993) DM-9384, a new cognition-enhancing agent, increases the turnover of components of the GABAergic system in the rat cerebral cortex. Eur J Pharmacol 238:303–309
Watanabe T, Matsuhashi K, Shimada M et al. (1994) Reproductive toxicity studies of the new cognition-enhancing agent nefiracetam in rats and rabbits. Arzneim Forsch 44:239–242
Woodruff-Pak DS, Hinchliffe RM (1997) Mecamylamineor scopolamine-induced learning impairment: ameliorated by nefiracetam. Psychopharmacol 131:130–139
Yamada K, Nakayama S, Shiotani T et al. (1994) Possible involvement of the activation of voltage-sensitive calcium channels in the ameliorating effects of nefiracetam on scopolamine-induced impairment of performance in a passive avoidance task. J Pharmacol Exp Ther 270:881–892
Ehrhardt G, Ruschig H (1972) Arzneimittel, VCH, Weinheim: Bd.I, S. 174
Hansch C (1990) Comprehensive Medicinal Chemistry, 1st Ed., Pergamon Press, Oxford, S. 701
Dictionary of organic compounds (1965) Eyre & Spootswoode Publ., London, S.2304
Mar31, S.29
Drugs Fut (1993) 18(4):324-326
Hattox SE, Noms SH, Riska PS, Silverstein HH, George RS, Johnstone JN, Hargrave KD, Grob PM (1992) Drugs Fut 17:887–889
Kelly TA (1996) US Pat, zit. nach CA 125:142791
Kelly TA, Terence A, Patel UR (1995) J Org Chem 60:1875–1877
Ple N, Turck A, Couture K, Queguiner G (1996) Synthesis S:838-842
Grozinger KG, Fuchs V, Hargrave KD, Mauldin S, Vitous J, Campbell S, Adams J (1995) J Heterocycl Chem 32:259–263
Hargrave KD, Proudfoot JR, Grozinger KG, Cullen E, Kapadia SR, Patel UR, FuchsVU, Mauldin SC, Vitous J et al. (1991) J Med Chem 34:2231–2241
Norman MH, Minick DJ, Martin GE (1993) J Heterocycl Chem 30:771–779
Palladino DEH, Hopkins JL, Ingraham RH, Warren TC, Kapadia SR, Van Moffaert GJ, Grob PM, Stevenson JM, Cohen KA (1994) J Chromatogr A 676:99–112
Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411–1413
Richman D, Rosenthal AS, Skoog M, Eckner RJ, Chou TC, Sabo JP, Merluzzi VJ (1991) BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 35:305–308
Viraimune® Prescribing Information, Boehringer Ingelheim (1997) (online: http://www.viramune.com/Product-Info/FullPrescribinglnfo.html)
Cheeseman SH, Hattox SE, McLaughlin MM, Koup RA, Andrews C, Bova CA, Pav JW, Roy T, Sullivan JL, Keirns JJ (1993) Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 37:178–182
Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M (1995) High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 171:537–545
Flieger M, Sedmera P et al. (1984) J Chromatogr 284:219–225, zit. nach CA (1984) 100:145058q
Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf
Trtik B (1987) Czech, zit. nach CA (1989) 110:13664j
Vachek J (1986) Czech, zit. nach CA (1987) 106:182777w
Neumann BW, Lauschner F (1979) Arzneim Forsch 29:1206
Fariello RG (1997) Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Functional Neurology, 12:221–225
Saletu B, Anderer P, Semlitsch HV (1997) Relations between symptomatology and brain function in dementias: double-blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline. Dementia and Geriatric Cognitive Disorders, 8(Suppl. 1): 12–21
Saletu B, Paulus E, Linzmayer L, Anderer P, Semlitsch HV, Grunberger J, Wicke L, Neuhold A, Podreka I (1995) Nicergoline in senile dementia of Alzheimer type and multi-infarkt dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 11/.385–395
Mimori Y, Nakamura S, Yukawa M (1997) Abnormalities of acetylcholinesterase in Alzheimer’s disease with special reference to effect of acetylcholinesterase inhibitors. Behavioural Brain Research 83:25–30
Carfagna N, Di Clemente A, Cavanus S, Damiani D, Gerna M, Salmoiraghi P, Cattaneo B, Post C (1995) Modulation of hippocampal Ach release by chronic nicergoline treatment in freely moving young and aged rats. Neuroscience Letters 197:195–198
Carfagna N, Cavanus S, Damiani D, Salmoiraghi P, Fariello R, Post C (1996) Modulation of phosphoinostide turnover by chronic nicergoline in rat brain. Neuroscience Letters 209:189–192
Herrmann WM, Stephan K, Gaede K, Apeceche M (1997) A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dementia and Geriatric Cognitive Disorders. 8:9–17
Bottiger Y, Dostert P, Benedetti MS, Bani M, Fiorentini F, Casati M, Poggesti I, Alm C, Alvan G, Bertilsson L (1996) Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. Br J Clin Pharmacol 42:707–711
Meilhac B, Montestruc F, Aubin F, Dhian F, Rouffy J (1997) Double-blind randomized comparative study of nicergoline naftidrofuryl on the quality of life in chronic obliterative arteriopathy of lower limbs with intermittent claudication. Therapie 52:179–186
Pfitzenmeyer P, Foucher P, Dennewald G, Chevalon B, Debieuvre D, Bensa P, Piard F, Camus P (1996) Pleuropulmonary changes induced by ergoline drugs. European respiratory J. 9:1013–1019
Clarke’s (1986) Isolation and Identification of Drugs in Pharmaceutics, Bodyfluids and Post Mortem Material, Pharmaceutical Press, London, S. 806–807
Mar31, S. 915
Salmi HA, Frey H (1974) Nicotinic acid plasma concentrations after ingestion of 1,3,4,6-tetranicotinoyl-fructofuranose (tetranicotinoylfructose, nicofuranose). Curr Ther Res Clin Exp 16:669–674
Pankiewicz F (1965) Beitrag zur Therapie von Durchblutungsstörungen mit Tetranicotinoyl-fructofuranose (Nicofuranose). Ther Umsch 22:494–497
Kujira T, Matsunaga I, Mori T, Nagano H, Ogasawa T, Shindo M, Sugano S, Takaku S (1980) US 4,200,640; zit. nach CA 93 (1980) P 132382f
Xu J, Zeng S, Dai S, Zheng X (1986) Yaoxue Tongbao 21:273–275
Schwende FJ, Lewis RC (1990) J Chromatogr 525:151–160
Frampton J, Buckley MM, Fitton A (1992) Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 44:625–655
Hamilton TC, Weston AH (1989) Cromakalim, Nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. General Pharmacol 20:1–9
Goldschmidt M, Landzberg BR, Frishman WH (1996) Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease. J Clin Pharmacol 36:559–572
Knigth C, Purcell H, Fox K (1995) Potassium channel openers: clinical applications in ischemic heart disease — overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther 9(Suppl 2):229–236
Richer C, Pratz J, Mulder P, Mondot S, Giudicelli IF, et al. (1990) Cardiovascular and biological effects of K+ channel openers, a class of drug with vaosrelaxant and cardioprotective properties. Life Sciences 47:1693–1705
Suryapranata H, Serruys PW, De Feyter PJ, Verdouw PD, Hugenholtz PG (1988) Coronary vasodilatory action after a single dose of nicorandil. Am J Cardiol 61:292–297
Furukawa K, Itoh T, Kajiwara M, Kitamura K, Suzuki H (1981) Vasodilating actions of 2-nicotinamidoethyl nitrate on porcine and guinea pig coronary arteries. J Pharmacol Exp Ther 218:248–259
Nakae I, Quan L, Hashimot K, Sugimoto Y, et al. (1994) Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs. Cardiovasc Drugs Ther 8:137–145
O’Rourke ST (1996) KATP channel activation mediated nicorandil-induced relaxation of nitrate-tolerant coronary arteries. J Cardiovasc Pharmacol 27:831–837
Larsen AI, Goransson L, Aarsland T, Tamby JF, et al. (1997) Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J 134:435–441
Tabone X, Funck-Bretano C, Billon N, Jaillon P (1994) Comparison of tolerance of intravenous nitroglycerin during nicorandil and intermittent nitroglycerin patch in healthy volunteers. Clin Pharmacol Ther 56:672–679
Wolf DL, Jungbluth GL, Metztler CM, Froeschke MOE, et al. (1994) Acute effects of increasing doses of nicorandil on renal function in man. Int J Clin Pharmacol Ther 32:246–253
Baumbach A, Braun U, Doring G, Haase KK, et al. (1995) Double-blind comparison on the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility. Cardiovasc Drugs Ther 9(Suppl 2):213–220
Saito S, Mizumura T, Takayama T, Honye J, et al. (1995) Antiischemic effects of nicorandil during coronary angioplasty in humans. Cardiovasc Drugs Ther 9(Suppl 2):257–263
Grover GJ (1997) Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion. Can J Physiol Pharmacol 75:309–315
Robert E, Delye B, Aya G, Peray P, et al. (1997) Comparison of proarrhythmogenic effects of two potassium channel openers, levcromakalim (BRL 38227) and nicorandil (RP 46417): a high-resolution mapping study on rabbit heart. J Cardiovasc Pharmacol 29:109–118
Jaraki O, Strauss WE, Francis S, Loscalzo J, et al. (1994) Antiplatelet effects of a novel antianginal agent, nicorandil. J Cardiovasc Pharmacol 23:24–30
Kaski JC (1995) Management of vasopastic angina — role of nicorandil. Cardiovasc Drugs Ther 9(Suppl 2):221–227
Frydman AM, Chapelle P, Diekmann H, Bruno R, Thebault JJ (1989) Pharmacokinetics of nicorandil. American J Cardiol 63:25J–33J
Witchitz S, Darmon JY (1995) Nicorandil safety in the long-term treatment of coronary heart disease. Cardiovasc Drugs Ther 9(Suppl 2):237–243
Dornow A, Wedekind G (1953) Arch Pharm (Weinheim) 286:338–344
Papadopoulos EP, Jarrar A, Issidorides CH (1946) J Org Chem 31:615–616
Nakamoto K, Martell AE (1959) J Am Chem Soc 81:5857–5863
Laviron É (1961) Bull Soc Chim Fr: 2325-2349
Dictionary of organic compounds, (1965) 4. Aufl. Eyre & Spottiswoode, London
Auterhoff H, Kovar KA (1985) Identifizierung von Arzneistoffen, 5.Aufl., Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, S. 59
Klosa J (1955) Arch Pharm (Weinheim) 288:426–427
Etablissements Clin-Byla, Fr M 8,197 (1973) zit. nach CA 78:58455
Etablissements Clin-Byla, Ger Offen 1.932.844 (1970) zit. nach CA 72:90493
Negwer M (1994) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin, S. 2880
Mousseron M (1968) Fr. 1.489.07; zit. nach CA (1968) 69:19154
Negwer M (1994) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin, S. 2256
Carron M, Jullien A, Julien T, Garozynska C (1963) Ann Pharm Franc 21:287–297
Broquaire M, Guinebault PR (1981) J Liq Chromatogr 4:2039–2061
Tulus R, Gurkan T (1973) Univ Eczacilik Fak Mecm 9:63–76
Buisson Y, Larribaud J (1989) Therapie 44:123–26
Bouree P Chaput JC, Krainik et al. (1989) Gastroent Clin Biol 13:469–72
Ojasoo T (1987) Drugs Fut 12:763–770
Perronnet J, Girault P, Bonne C (1977) Ger Pat 2649925, zit nach CA 87: 85005z
Moguilewsky M, Fiet J, Tournemine C, Raynoud JP (1986) Pharmacology of an antiandrogen, anadron, used as an adjuvant therapy in the treatment of prostate cancer. J Steroid Biochem 24(1):139–146
Pendyala L, Creaven PJ, Huben R, Tremblay D, Bertagna C (1988) Pharmacokinetics of Anadron in patients with advanced carcinoma of the prostate. Cancer Chemother Pharmacol 22(1):69–76
Matveev BP, Bukharkin BV, Zhumagazin ZhD (1993) Lechenie antiandrogenami bol’nykh rakom predstatel’noi zhelezy s metastazami v kosti. Urol Nefrol Mosk (1):10–14
Cozinet B, Thomas G, Thalabard JC, Brailly S, Schaison G (1989) Effects of a pure antiandrogen on gonadrotropin secretion in normal women and in polycystic ovarian disease. Fertil Steril 52(1):42–50
Beland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD (1990) A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer 1; 66(5 Suppl):1074–1079
Janknegt RA (1993) Total androgen blockade with the use of orchiectomy and nilutamide (Anadron) or placebo as treatment of metastatic prostate cancer: Anadron International Study Group. Cancer 72(12 Suppl):3874–3877
Bertagna C, De Gery A, Hucher M, Francois JP, Zanirato J (1994) Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 73(4):396–402
Prostate Cancer Trialists’ Collaborative Group (1995) Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346(8970):265–269
Asscheman H, Gooren LJ, Peereboom Wynia JD (1989) Reduction in undesired sexual hair growth with anandron in male-to-female transsexuals experienees-with a novel androgen receptor blocker. Clin Exp Dermatol 14(5):361–363
Harnois C, Malenfant M, Dupont A, Labrie F (1986) Ocular toxicity of Anadron in patients treated for prostatic cancer. Br J Ophthalmol 70(6):471–473
Jonville AP, Diot E, Dutertre JP, Autret E (1992) Toxicité pulmonaire du nilutamide (Anadron). Bilan cooperatif des centres français de pharmacovigilance. Therapie 47(5):393–397
Hammel P, Ducreux M, Bismuth E, Ladouch-Badre A, Benoit G, Buffet C, Ettiente JP (1991) Nilutamide-induced acute hepatitis. Gastroenterol Clin Biol 15(6–7):557
Rouger-Barbier D, Delefosse D, Pamphile R, Goldfarb G (1989) Absence de manifestation clinique et biologique après absorption massive de nitulamide. J Toxicol Clin Exp 9(2):77–82
Babany G, Tinel M, Letteron P, Freneaoux E, Berson A, Larrey D, Pessayre D (1989) Inhibitory effects of nilutamide, a new androgen receptor antagonist, on mouse and human liver cytochrome P-450. Biochem Pharmacol 38(6):941–947
Moore GGJ, Lappi LR, Can 996577, zit. nach CA (1977) 86:29488
Moore GGJ, Lappi LR, US 3856859, zit. nach CA (1975) 82:170368
Fernandez Otero GC, Carducci CN (1991) J Liq Chromatogr 14(8):1561–1573
Nonzioli A, Luque G, Fernandez C (1989) J High Resolut Chromatogr 12(6):413–416
Castoldi D, Monzani V, Tofanetti O (1988) J Chromatogr 425(2):413–418
Magni E (1993) The effect of nimesulid on prostanoid formation. Drugs Suppl 1:10–14
Carr DP, Henn R, Green JR (1986) Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastrointestinal toxicity of non-steroidal anit-inflammatory drugs in rat. Agents Actions 18:374–375
Swingle KF, Moore GG, Grant TJ (1971) 4-nitro-2-phenoxymethansulfonanilide (R-805): a chemically novel antiinflammatory agent. Arch Int Pharmacodyn Ther 221(1):132–139
Swingle KF, Chang SF, Erickson EH (1978) Impaired metabolic handling of drugs in rats with arthritis induced by 6-sufonanilamidoindazole. Biochem Pharmacol 27(20):2395–2398
Rossoni G, Berti F, Buschi A, Villa LM, Bella DD (1993) New data concerning the antianaphylactic and antihistaminic of nimesulide. Drugs 46 Suppl 1:22–28
Maffei Facino R, Carini M, Aldini G, Saibene L, Macciocchi A (1993) Antioxidant profile of nimesulide, indomethacin and diclofenac in phosphatidylcholine liposomes (PCL) as membrane model. Int J Tissue React 15(6):225–234
Pelletier JP, Martel-Pelletier J (1993) Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs 46 Suppl 1:34–39
Verhoeven AJ, Tool AT, Kuijpers TW, Roos D (1993) Nimesulide inhibits platelet-activating factor synthesis in activated human neutrophils. Drugs 46 Stuppl 1:52–58
Vane JR, Botting RM (1995) A better understanding of anti-inflammatory drugs based on isoforms of COX. Adv Prost Thromb Leuko Res 23:41–48
Famaey JP (1997) In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulid: An overview. Inflamm Res 46:437–446
Ward A, Brogden RN (1988) Nimesulide. A preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states. Drugs 36(6):732–735
Schärli AF, Brühlhart K, Monti T (1990) Pharmacokinetics and therapeutic study with nimesulide suppositories in children with post-operative pain and inflammation. J Int Med Res, 18(4):315–321
Ambrosioni E (1986) Farmacologia della nimesulide. Attualita Terapeutica Internazionale 33:7
Bernareggi A (1993) The pharmacokinetic profile of nimesulide in healthy volunteers. Drugs 46 Suppl 1:64–72
Castoldi D, Monzani V, Tofanetti O (1988) Simultaneous determination of nimesulide and hydroxynimesulide in human plasma and urine by high-performance liquid chromatography. J Chromatogr 425(2):413–418
Maffei Facino R, Carini M, Brambilla A, Casciarri I, Scareicabarozzi I, et al. (1989) Metabolism of nimesulide in man and radical scavenging activity of its main metabolites. 3rd Interscience World Congress on Antirheumatics, Analgesics, Immunomodulators, Montecarlo, March 15–18, Abstract Book, p.244
Reiner M, Magni E (1982) Efficacy and safety of nimesulide in the short-term treatment of rheumatoid arthritis. Curr Ther Res 31:906–912
Reiner M (1982) Nimesulide in the short-term treatment of osteoarthrosis: a pilot study for assessing the minimal effective dose. J Int Med Res 10(2):92–98
Pochobradsky MG, Mele G, Beretta A, Montagnani G (1991) Post-marketing survey of nimesulide in the short-term treatment of osteoarthritis. Drugs Exp Clin Res 17(3):197–204
Gallucci M, Toscani F, Mapelli A, Cantarelli A, Veca G, Scaricabarozzi I (1992) Nimesulide in the treatment of advanced cancer pain. Double-blind comparison with naproxen. Arzneimittelforschung 42(8):1028–1030
Toscani F, Gallucci M, Scaricabarozzi I (1993) Nimesulide in the treatment of advanced cancer pain. Double-blind comparison with naproxen. Drugs 46 Suppl 1:156–158
Reiner M, Massera E, Magni E (1984) Nimesulide in the treatment of fever: a double-blind, crossover clinical trial. J Int Med Res 12(2):102–107
Rondel RK, Eberhardt R, Koch J, et al. (1984) Treatment of primary essential dysmenorrhoea with nimesulide in a double-blind crossover study. Curr ther Res 35:123–129
Pulkkinen MO (1987) Alternations in intrauterine pressure, menstrual fluid prostaglandin F levels, and pain in dysmenorrheic women treated with nimesulide. J Clin Pharmacol 27(1):65–69
Lecomte J, Monti T, Pochobradsky MG (1991) Antipyretic effects of nimesulide in paediatric practice: a doubleblind study. Curr Med Res Opin 12(5):296–303
D’Apuzzo V, Monti T (1992) Pilot study of the antipyretic and analgesic activity of nimesulide paediatric suppositories. Drugs Exp Clin Res 18(2):63–68
Fossaluzza V, Montagnani G (1989) Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double-blind trial versus naproxen. J Int Med Res 17(3):295–303
Perucca E (1993) Drug interactions with nimesulide. Drugs 46 Suppl 1:79–82
Steinhäuslin F, Munafo A, Buclin T, Macciocchi A, Biollaz J (1993) Renal effects of nimesulide in furosemidtreated subjects. Drugs, 46 Suppl 1:257–262
Auteri A, Blardi P, Bruni F, Domini L, Pasqui AL, Saletti M, Verzuri MS, Scaricabarozzi I, Vargui G, Di Perri T (1991) Pharmacokinetics and pharmacodynamics of slow-release theophylline during treatment with nimesulide. Int J Clin Pharmacol Res 11(5):211–217
Baggio E, Maraffi F, Montalto C, Nava ML, Torti L, Caciarri I (1993) A clinical assessment of the potential for pharmacological interaction between nimesulide and digoxin in patients with heart failure. Drugs, 46 Suppl 1:91–94
Ruhemann (1910) J Chem Soc: 1438-1449
Teeters, Shriner (1933) J Am Chem Soc 55:3026–3028
McCaldin (1960) Chem Rev 60:39–51
Schönberg, Singer (1978) Tetrahedron 34:1285–1300; Schönberg, Azzam (1993) J Chem Soc:1428-1430
Purvis (1911) J Chem Soc:1953-1960
Shiratsuchi M, Shimizu N, Shigyo H, Kyotani Y, Kunieda H, Kawamura K, Sato S, Akashi T, Nagakura M (Kowa Co., Ltd.) Eur Pat Appl 42299; Jpn K 8207481 und 82106619; zit. nach Thorpe PJ (1983) Drugs Fut 8:497-499
Shiratsuchi M, Kawamura K, Akashi T, Fujii M, Ischihama H, Uchida Y (1987) Chem Pharm Bull 35:632–641
Shiratsuchi M, Kawamura K, Akashi T, Ishihama H, Nakamura M, Takenaka F (1987) Chem Pharm Bull 35:3691–3698
Ward JE, Coles P, Cox H, Eisenhofer G, Angus JA (1992) Relationship between the symphatholytic action of nebivolol and hypotension. J Cardiovasc Pharmacol 20:115–124
Adachi T, Hori S, Miyazaki K, Takahashi E, Nakagawa M, Udagawa A, Hayashi N, Aikawa N, Ogawa S (1995) Rapid increase in plasma nitrite concentration following intravenous administration of nipradilol. Eur J Pharmacol 286:210–204
Sasage H, Nakazawa M, Arakawa M, Imai S (1995) Contribution of cyclic GMP generation to the relaxation by nipradilol in the rabbit aorta. Gen Pharmacol 26:85–91
Lamping KG, Bloom EN (1995) Comparison of coronary microvascular response to nipradilol and nitroglycerin. Pharmacology 51:315–322
Sugano S, Kawafune T, Suzuki T, Kubota M, Okajima T, Sumino Y, Akita H (1995) Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new beta-blocker with nitrovasodilating properties in patients with liver cirrhosis. Am J Gastroenterol 90:788–793
Yoshikawa T, Handa S, Akaishi M, Mitamura H, Ogawa S (1995) Beta-1-selectivity is not essential to achieve therapeutic efficacy with beta-blockade therapy for idiopathic dilated cardiomyopathy. Cardiology 86:217–223
Bäckström R, Honkanen E, Pippuri A, Karisalo P, Pystynen J, Heinola K, Nissinen E, Linden IB, Mannisto PT (1989) J Med Chem 32:841–846
Taskinen J, Wikberg T, Ottoila P, Kanner L, Lotta T, Pippuri A, Bäckström R (1991) Drug Metab Dispos 19:178–183
Wikberg T, Taskinen J (1993) Drug Metab Dispos 21:325–333
Schultz E, Nissinen E (1989) Biochem Pharmacol 38:3953–3956
Nissinen E, Linden IB, Schultz E, Kaakkola S, Männistö PT, Potho P (1988) Eur J Pharmacol 153:263–269
Aho P, Linden IB, Nissinen E, Pohto P (1988) Dig Dis Sci 33:897
Aho P, Linden IB, Nissinen E, Pohto P (1988) Dig Dis Sci 33:905
Aho PA, Linden IB (1992) Scand J Gastroenterol 27:134–138
Feimström G, Säfsten B (1994) Dig Dis Sci 39:1839–1842
Dibbern HW, Wirbitzki E (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf, Nr. 3087
Mar 29, S. 1595
Keller K, Greiner S, Stockebrand S (1990) Homöopathische Arzneinmittel, Govi-Verlag, Bd.2
Keller K, Greiner S, Stockebrand P (1990) Homöopathische Arzneimittel, Govi-Verlag: Bd. 2
Boericke W (1994) Horn. Mittel und ihre Wirkungen, Wissenschaftl. Autorenverlag Leer/Ostfriesland: S. 238-239
DHU, Karslruhe (1994) S. 148-149
Voisin H (1969) Materia medica des hom. Praktikers, Haug Verlag Heidelberg: S. 586
Kakác B, Vejdelek ZJ (1974) Handbuch der photometrischen Analyse organischer Verbindungen, Verlag Chemie, Weinheim, S. 709
Medwick T (1961) Metal-Containing Organic Compounds. In: Higuchi T, Brochmann-Hanssen E (Hrsg.) Pharmaceutical Analysis, Interscience Publishers, New York London Sydney, S. 711–734
Mar 31, S. 1139
Lorenz W, Behnisch R, Mietzsch R (1948) U.S. 2:443,742, zit. nach CA 42:8822e
Negwer M (1994) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin, S. 1314
Petrow V, Sturgeon B (1954) J Chem Soc 570
Chephasaar (1991) Basisinformation Nitroxolin, S. 1-23
Von Rütte B, Delnon I (1968) Der chronische Harnweginfekt und seine Behandlung mit Nibiol, Schweiz Med Wochenschr 98:1864–1868
Brühl P (1983) Zur aktuellen Resistenzsituation von Erregern bei Harnwegsinfektionen, Therapiewoche 33:4084–4088
Bourlioux P, Amgar A (1988) Etude multicentrique de la surveillance de la résistance à sept antibiotiques de germes isolés d’infections urinaires, Sem Hôp Paris 64:86–90
Michel-Nguyen A, Nourrit J, Penand A, Nicoli RM (1986) Nitroxoline et antifongiques traditioneis. Comparaison de leur activité antifongique sur 238 souches de levures (+), Bull Soc Fr Mycol Méd 15:265–268
Rödel B (1987) 8-Chinolinole, ausgewählte klinisch interessierende Derivate. In: Kramer A, Weuffen W, Krasilnikow AP, Gröschel D, Bulka E, Rehn D (Hrsg.) Antibakterielle, antifungielle und antivirale Antiseptik — ausgewählte Wirkstoffe, Handbuch der Antiseptik, Bd. II/3, Volk u. Gesundheit, Berlin, S. 345–350
Dufour A, Bollack C (1979) De le pénétration de la Nitroxoline dans le parenchyme prostatique. Essai thérapeutique, J Urol Néphrol 3:207–212
Mrhar A, Kopitar Z, Kozjek F, Presl V, Karba R (1979) Clinical pharmacokinetics of nitroxoline, Int J Clin Pharmacol Biopharm 17:476–481
Bergogne-Berezin E, Berthelot G, Muller-Serieys C (1987) Actualité de la Nitroxoline, Pathol Biol 35:873–878
Dodat H, Chavrier Y, Dyon JF, AubertD, Galifer RB, Montupet P, Morisson-Lacombe G, Moscovici J, Valla J (1988) Etude clinique multicentrique comparative de la nitroxoline versus cotrimoxazole dans le traitement préventif de l’infection urinaire chez l’enfant, Gazette Méd 95:56–59
Lenzner A (1983) Orale Behandlung von Pilzerkrankungen des Harntraktes mit Nitroxolin, Therapiewoche 33:1735–1738
Sachse D (1984) Therapie chronisch-rezidivierender Harnwegsinfekte mit Nitroxolin, Therapiewoche 34:228–230
Cancet B, Amgar A (1987) Activité antifongique de la nitroxoline in vitro, Pathol Biol 35:879–881
Frobert JL, Coupry A (1987) Traitement par Nibiol forte des infections des voies urinaires basses non compliquées chez la femme, Gazette Méd 94:71–74
Simon C, Stille W (1989) Antibiotikatherapie in Klinik und Praxis, 7. Aufl., Schattauer; S. 284
Kramer A, Rozsahegyil, Weuffen W (1985) Chronische Vergiftungen durch Antiseptika. In: Kramer A, Berencsi G, Weuffen W (Hrsg.) Toxische und allergische Nebenwirkungen von Antiseptika, Handbuch der Antiseptik, Bd. I/5, Volk u. Gesundheit, Berlin, S.217
NN (1988) Nitroxolin: Ermittlungen zur Wirksamkeit und Häufigkeit unerwünschter Wirkungen, Bundesgesundheitsblatt 31:281
Schneider H, Coper H (1968) Morphologische Befunde am Zentralnervensystem der Ratte nach Vergiftung mit Antimetaboliten des Nicotinamids (6-Aminonicotinsäureamid und 3-Acetylpyridin) und einem Chinolinderivat (5-Nitro-8-hydroxychinolin), Arch Psychiat Z Ges Neurol 211:138–154
Chephasaar (1991) Interne Untersuchungen. Briefl Mitt
Kommission der EG (1990) Vorschlag für eine Richtlinie des Rates zur Angleichung der Rechtsvorschriften der Mitgliedstaaten über kosmetische Mittel, Brüssel, 29.10.1990
Raduechel B, Skuballa W, Vorbrueggen H (1985) DE 3543991 Al, zit. nach CA (1987) 107:96503
Skuballa W, Raduechel B, Vorbrueggen H, Elgers Wet al. (1984) US 4444788 A, zit. nach CA (1984) 101:151672
Krause W, Jakobs U, Buckenauer R, Biese H (1990) Prostaglandins 40:283–296
Konturek SJ, Brzozowski T, Drozdowicz D, Krzyzek E, Garlicki J, Majka J, Dembinski A, Stachura J, Amon I (1991) Eur J Pharmacol 195:347–357
Konturek SJ, Konturek JW, Kwiecien N, Obrulowicz W, Olesky J, Hebzda Z, Arnon I (1991) Scand J Gastroenterol 26:231–236
Konturek SJ, Kwiecien N, Obtulowicz W, Maczka J, Hebzda Z, Oleksy J (1991) Scan J Gastroenterol 26:1145–1151
Bilski J, Konturek SJ (1994) J Physiol Pharmacol 45:541–553
Täuber U, Brudny-Klöppel M, Jakobs U, Madetzki C, Mahler m (1993) Eur J Clin Pharmacol 44:497–500
Booher RN, Pohland A (1975) J Med Chem 18:266–268
Montzka TA, Matiskella JD, Partyka RA (1974) Tetrahedron Lett 1325-1328
Pohland A (Eli Lilly) (1962) U.S.-Pat. 3021360, zit. nach CA (1962) 57:P4594a
Billings RE, Booher R, Smits S, Pohland A, McMahon RE (1973) J Med Chem 16:305–306
Lau DHM, Henderson GL (1976) J Chromatogr 129:329–338
Kiang C, Campos-Flor S, Inturrisi CE (1981) J Chromatogr 222:81–93
Mar31, S.57
Haefely W, Kyburz E, Gerecke M, Möhler H (1985) Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure-activity relationship of their agonists and antagonists, Adv Drug Res 14:165–322
Klotz U (1984) Clinical pharmacology of benzodiazepines, Prog Clin Biochem Med 1:117–167
Affinito P, Monterubbianesi M, Primizia M et al. (1993) Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: Gestodene/ethinylestradiol and norgestimate/ethinylestradiol. Gynecol Endocrinol 7:259–266
Bringer J (1992) Norgestimate: a clinical overview of a new progestin. Am J Obstet Gynecol 166:1969–1977
Burkman RT (1995) The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 98:130–136
Carr BR (1997) Re-evaluation of oral contraceptive classifications. Int J Fertil Womens Med, Suppl 1, 133–144
Genazzani AR, Petraglia F, Cleva M et al (1989) Norgestimate increases pituitary and hypothalamic concentrations of immunoreactive beta-endorphin. Contracept 40:605–613
Gidwani GP (1998) Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebocontrolled trial. Clin Pediatr 37:52
Hull ME, Moghissi KS (1986) Effects of norgestimate (0.250 mg) in combination with ethinyl estradiol (0.035 mg) on cervical mucus. Adv Contracept 2:71–77
Kaplan B (1995) Desogrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 29:736–742
Kuhl H (1996) Comparative pharmacology of newer progestogens. Drugs 51:188–215
Kuhnz W, Blode H, Mahler M (1994) Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. Contracept 49:255–263
Lucky AW, Henderson TA, Olson WH et al. (1997) Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 37:746–754
Madden S, Back DJ (1991) Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro. J Steroid Biochem Mol Biol 38:497–503
Redmond GP, Olson WH, Lippman JS et al. (1997) Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 89:615–622
Samsioe G (1992) Introduction to steroids in the menopause. Am J Obstet Gynecol 166:1980–1985
Schwingl PJ, Shelton J (1997) Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives. Contracept 55:125–129
Shenfield GM, Griffin JM (1991) Clinical pharmacokinetics of contraceptive steroids. An update. Clinical Pharmacokinet 20:15–37
Sobel NB (1994) Progestins in preventive hormone therapy. Including pharmacology of the new progestins, desogestrel, norgestimate, and gestodene: are there advantages? Obstet Gynecol Clin North Am 21:299–319
Thorogood M (1998) Oral contraceptives and thrombosis. Curr Opin Hematol 5:350–354
Vandenbroucke JP, Heimerhorst FM, Bloemenkamp KW et al. (1997) Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 177:887–891
Wiegratz I, Jung-Hoffmann C, Gross W et al. (1998) Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contracept 58:83–91
Schnider O, Grüssner A (1951) Helv. Chim. Acta 271:2211–2217
Hansch C (1991) Comprehensive Medicinal Chemistry, Pergamon Press, Oxfords, Bd.6, S.722
Stead AH, Gill R, Wrigt T, Gibbs JP, Moffat AC (1982) Analyst 107:1106–1168
Braun J (1914) Chem. Ber. 47:2312–2330
Speyer E, Walther L (1930) Chem. Ber. 63:852–855
Moffat AC (1986) Clarke’s Isolation and Identification of Drugs, 2nd Ed., The Pharmaceutical Press, London, S. 825
Jane I, McKinnon A, Flanangan RJ (1985) J Chromatogr 323:191–225
Boerner U, Roe RL, Becker CE (1974) Detection, isolation and characterization of normorphine and norcodeine as morphine metabolites in man. J Pharm Pharmacol 26:393–398
Gillan MG, Kosterliltz HW, Paterson SJ (1980) Comparison of the binding characteristics of tritiated opiates and opioid peptides. Br J Pharmacol 70:481–490
Bockmühl M, Ehrhart G (1949) Liebigs Ann Chem 561:52–85
Beilstein, Erg. III/IV, Bd. 20/2, S. 914
Moffat AC (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London, S. 825
Beckett AH (1956) J Pharm Pharmacol 8:848–859
Badiru SO, Jeffries TM (1988) J Pharm Biomed Anal 6:859–866
Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin
Ebel S (1977) Handbuch der Arzneimittelanalytik, Verlag Chemie, Weinheim New York, S. 309–315
Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf, S. 2127
Zingales I (1968) J Chromatogr 34:44–51
Knox JH, Jurand J (1975) J Chromatogr 103:311–326
Norheim G (1974) J Chromatogr 88:403–406
Baldessarini RJ (1989) J Clin Psychiatry 50;117–126
Baldessarini RJ (1985) Chemotherapy in psychiatry: Principles and practice. Cambridge, mass. Hardvard University Press: 130–223
Baldessarini RJ (1982) McLean Hosp J 7:1–27
Hegerl U, Müller HJ (1996) Psychopharmakotherapie 1:13–26
Morris JB, Beck AT (1974) Arch Gen Psychiatry 30:667–674
Richelson E, Pfenning M (1984) Eur J Pharmacol 104:277–286
Richelson E (1981) Tricyclic antidepressants: interaction with histamine and muscarinic acetylcholine receptors. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York: 53–73
Peroutika SJ, Snyder SH (1981) Interactions of antidepressants with neurotransmitter receptor sites. IN: Enna SJ, Malick JB, Richelson E (Hrsg.) Anitdepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York 75–90
Möller-Nielsen I (1980) Tricyclic antidepressants: General pharmacology. In: Born GVR, Farah A, Herken H, Welch AD (Hrsg.) Handbook of experimental pharmacology, Vol. 55/I. Hoffmeister F, Stille G (Hrsg.) Psychotropic agents Parti: Antipsychotics and antidepressants. Springer-Verlag, Berlin Heidelberg New Yrok:399–414
Shein K, Smith SE (1978) Br J Pharmacol 62:567–571
Delini-Stula A (1993) Experimentelle und klinische Pharmakologie. In: Riederer P, Laux G, Pöldinger W (Hrsg.) Neuro-Psychopharmaka Bd. 3: Antidepressiva und Phasenprophylaktika. Springer-Verlag Wien 20–25
Mobley PL, Sulser F (1981) Down regulation of central noradrenergic receptor system by antidepressant therapies: Biochemical and clinical aspects. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants. Neurochemical, behavioral, and clinical perpectives. Raven Press, New York 31–51
Sulser F (1983) Psychopharmacol Bull 19:300–304
Babington RG (1981) Neurophysiologic techniques and antidepressive activity. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven press, New York: 157–173
Gram LF, Overo KF (1975) Clin Pharmacol Ther 18:305–314
Rubin EH, Biggs JT, Prescorn SH (1985) J Clin Psychiatry 46:418–424
Pollock BG, Perel JM (1989) Can J Psychiatry 34:609–617
Ziegler VE, Co BT, Taylor JR, Clayton PJ, Biggs JT (1976) Clin Pharmacol Ther 19:795–801
Asberg M, Crönholm B, Sjöqvist F, Tuck D (1971) Br Med J 3:331–334
Oliveira IR, Do-Prado-Lima PAS, Samuel-Lajeunesse B (1989) Psychiatr Psychobiol 4:43–60
Perry PJ, Pfohl BM, Holstad SG (1987) Clin Pharmacokinet 13:381–392
Dahl ML, Nordin C, Bertilsson L (1991) Ther Drug Monit 13:189–194
Brosen K (1990) Clin Pharmacokinet 18:220–239
Coutts RT (1994) J Psychiatr Neurosci 19:30–44
Eichelbaum M, Gross AS (1990) Pharmacol Ther 46:377–394
Dahl-Puustinen ML, Perry TL, Dumont G, von Bahr C, et al. (1989) Clin Pharmacol Ther 45:650–656
Georgotas A, McCue RE, Cooper TB, Nagachandran N, et al. (1988) Arch Gen Psychiatry 45:929–932
Roszinsky-Köcher G (1995) Psychopharmakotherapie 2:15–18
Perry PJ, Browne JL, Alexander B, Tsuang MT, et al. (1984) Clin Pharmacokinet 9:555–563
Möller HJ, Schmauß M (1996) Arzneimitteltherapie in der Psychiatrie. Wissenschaftl. Verlagsgesellschaft Stuttgart
Benkert O, Hippius H (1996) Psychiatrische Pharmakotherapie. Springer, Berlin Heidelberg New York
Eckert A, Reiff J, Müller W (1989) Psychopharmakotherapie 5:8–18
Baldessarini RJ (1990) Drugs and the treatment of psychiatric disorders: In: Goodman GA, Rall TW, Nies AS, Tylor P (Hrsg.) Goodman and Gilman’s The pharmacological basis of therapeutics. 8th edition. Macmillan, New York 383–435
Thomann P, Hess R (1980) Toxicology of antidepressants. In:. Born GVR, Farah A, Herken H, Welch AD (Hrsg.) Handbook of experimental pharmacology, Vol. 55/I. Hoffmeister F, Stille G (Hrsg.) Psychiotropic agents Part I: Antipsychotics and antidepressants. Springer-Verlag, Berlin Heidelberg New York:527–549
Vohra J, Burrows G, Hunt D, Slowmann G (1975) Eur J Cardiol Excerpta Medica 3:219–227
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
von Bruchhausen, F. et al. (1999). N. In: von Bruchhausen, F., et al. Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58388-9_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-58388-9_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63569-4
Online ISBN: 978-3-642-58388-9
eBook Packages: Springer Book Archive